Industry News
Biotechnology Industry News
After COVID and new global disruptions, Eli Lilly does victory lap with UC data
After COVID and new global disruptions, Eli Lilly does victory lap with UC data aarmstrong Mon, 05/23/2022 - 14:27
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin out preps FDA filing
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin out preps FDA filing gmasson Mon, 05/23/2022 - 10:54
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spinout preps FDA filing
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spinout preps FDA filing gmasson Mon, 05/23/2022 - 10:54
Biohaven flunks first clinical test for rare disease drug post-Pfizer sell-off
Biohaven flunks first clinical test for rare disease drug post-Pfizer sell-off mbayer Mon, 05/23/2022 - 10:16
Chasing Lilly and Pfizer, Concert’s JAK inhibitor hits high notes in phase 3 alopecia trial
Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial ntaylor Mon, 05/23/2022 - 08:41
J&J’s $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential ntaylor Mon, 05/23/2022 - 05:29
Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public attack
Zymeworks rejects All Blue's $773M offer as an 'opportunistic' public attack aarmstrong Fri, 05/20/2022 - 10:53
Not an ‘excellent outcome’ for Athersys stock as stem cell therapy misses endpoint in Japanese trial
Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial jwaldron Fri, 05/20/2022 - 09:45
100% overall survival data for gene therapy fuel Rocket for flight to regulators
100% overall survival data for gene therapy fuel Rocket for flight to regulators aarmstrong Fri, 05/20/2022 - 09:41
Terremoto spells out plan to expand covalent drug alphabet with $75M funding
Terremoto spells out plan to expand covalent drug alphabet with $75M funding jwaldron Fri, 05/20/2022 - 07:33
Death triggers FDA hold on Foghorn blood cancer clinical trial, shrouding timing of data drop
Death triggers FDA hold on Foghorn blood cancer clinical trial, shrouding timing of data drop ntaylor Fri, 05/20/2022 - 06:15
Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient death
Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient death ntaylor Fri, 05/20/2022 - 05:17
Pfizer’s Arena goal? Get out of the way and don’t ‘break the new toy’
Pfizer's Arena goal? Get out of the way and don't 'break the new toy' aarmstrong Thu, 05/19/2022 - 15:44
Chutes & Ladders—Aquestive CEO heads for the exits while seizure med remains in regulatory limbo
Chutes & Ladders—Aquestive CEO heads for the exits while seizure med remains in regulatory limbo mbayer Thu, 05/19/2022 - 15:21
Calling all Fierce 15 fans: Nominations for the 2022 Fierce Biotech Fierce 15 are now open
Calling all Fierce 15 fans: Nominations for the 2022 Fierce Biotech Fierce 15 are now open aarmstrong Thu, 05/19/2022 - 12:59
Inceptor Bio to use $37M series A to nudge CAR-T toward clinic, establish manufacturing base
Inceptor Bio to use $37M series A to nudge CAR-T toward clinic, establish manufacturing base jwaldron Thu, 05/19/2022 - 09:40
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development mbayer Thu, 05/19/2022 - 08:48
Enanta sinks to multiyear low as phase 2b RSV trial flames out
Enanta sinks to multiyear low as phase 2b RSV trial flames out ntaylor Thu, 05/19/2022 - 06:45
Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 data
Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 data ntaylor Thu, 05/19/2022 - 05:52
Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce
Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce mbayer Wed, 05/18/2022 - 15:26